Medpace Holdings, Inc. (BMV:MEDP)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 209.17B |
| Revenue (ttm) | 48.28B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 286.66 |
| PE Ratio | 25.20 |
| Forward PE | 23.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34 |
| Average Volume | 323 |
| Open | 7,022.03 |
| Previous Close | n/a |
| Day's Range | 7,022.03 - 7,022.03 |
| 52-Week Range | 5,764.00 - 7,022.03 |
| Beta | n/a |
| RSI | 65.56 |
| Earnings Date | Apr 22, 2026 |
About Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man... [Read more]
Financial Performance
In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.
Financial numbers in USDNews
Medpace Flags Rising Cancellations, Near-Term Growth Uncertain
Medpace Holdings, Inc. (NASDAQ: MEDP) stock is trading lower on Thursday after the company reported its first-quarter earnings performance.
Medpace Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 26.5% revenue growth and strong new business awards, but elevated cancellations and weaker gross bookings led to a net book-to-bill of 0.88. Guidance remains unchanged, with management focused on improving win rates and expanding the pipeline.
Medpace Holdings, Inc. Reports First Quarter 2026 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Revenu...
MEDP INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Action Lawsuit
SAN DIEGO, April 15, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and Februa...
Shareholders who lost money in Medpace Holdings, Inc. (NASDAQ: MEDP) Should Contact Wolf Haldenstein Immediately
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (“Medpace” or the Company”) (...
MEDP INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Action Lawsuit
SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and Fe...
Medpace Holdings, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Medpace Holdings, Inc. , (“ Medpace " or the "Company") ( NASDAQ : MEDP) investors that the firm has initiated an investig...
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 2...
Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
(NASDAQ: MEDP) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders...
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, ...
Medpace Holdings Earnings Call Transcript: Q4 2025
Revenue grew 20% in 2025 with strong new business awards, but Q4 saw record cancellations, mainly in metabolic. 2026 guidance projects 9-13% revenue and EBITDA growth, with oncology leading bookings and AI investments expected to have a neutral near-term impact.
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Finan...
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2025 financial results after the market close on M...
Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings
Medpace Holdings Inc. (NASDAQ:MEDP) posted better-than-expected third-quarter earnings on Thursday.
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
Medpace Holdings Inc. (NASDAQ:MEDP) is trading higher on Thursday after the company released third-quarter earnings.
Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back
The company's new orders soared 49% in the third quarter from a year ago.
Medpace Holdings Earnings Call Transcript: Q3 2025
Q3 2025 delivered record bookings, 23.7% revenue growth, and a 1.20 book-to-bill, with backlog and pre-backlog both rising. 2025 guidance was raised, and 2026 is expected to see low double-digit revenue growth, with pass-through costs remaining elevated.
Medpace Holdings, Inc. Reports Third Quarter 2025 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Re...
Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2025 financial results after the market close on Wednesday, October...
Medpace Holdings Earnings Call Transcript: Q2 2025
Q2 2025 delivered strong revenue and EBITDA growth, driven by fewer cancellations, improved funding, and a shift toward faster-burning therapeutic areas. Guidance for 2025 was raised, with expectations for continued elevated reimbursable costs and accelerated hiring in the second half.
This Clinical Trials Stock Just Soared 40%. What Caused It to Pop.
If gains hold, that'd be the stock's largest single-day increase on record.
Top 2 Health Care Stocks You May Want To Dump This Quarter
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Medpace Holdings, Inc. Reports Second Quarter 2025 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Reven...
Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, ...